Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2?P-TIMI 50 Trial.
Xu H, Bonaca MP, Goodrich E, Scirica BM, Morrow DA. Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2?P-TIMI 50 Trial. Eur Heart J Acute Cardiovasc Care. 2021 04 08; 10(2):190?199.